bioscrip inc focus provid home
altern site infus therapi via platform
reason report
estim chang analysi sales/earn
tough start far fewer distract
despit tough start year driven primarili coupl
extern factor make steep ramp hit guidanc
oper improv continu signific y/i go-
arefewerdistractionsincludingtheinitialimpactofthecuresact
singl repeat model captur market share
take revenu million
take revenu million
million y/i ebitda million
partial day compani estim million impact
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
vision goal transform bio industri leader initi includ field forc effect
continuedunlockingofsupplychainopportun eightfigureopportun enhancedrevenuecyclemanag
cure act relief
discount back
thousand except per share
total revenu
sell gener administr expens
depreci amort
incom continu oper
pre-tax incom loss continu oper
net incom loss continu oper
accru dividend prefer stock
deem dividend prefer stock
net incom loss common
sell gener administr expens
compani report stephen inc
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
